E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

  • Law Blogs

Become a Fan

« USPTO News Briefs | Main | Biotech/Pharma Licensing News »

February 20, 2012

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d83451ca1469e20168e7b78d9b970c

Listed below are links to weblogs that reference Impact of Advances in DNA Sequencing Technology on Genetic Diagnostic Testing:

Comments

Interesting post.

I presume you are not suggesting that a business actually would be able to keep secret - for long - the location or sequence of a gene - true ? If you think that can be done, how long do you envision for the life of the secret?

Moving past those points, how would trade secret protection work with a diagnostic genomic project that will depend for validity on replication by other scientists?

Yet again innovation is poised to kill off legal systems of the past.

Dear Kirk: I think there is a place for multigenic diseases for the pattern of disease-relsted mutations to be kept secret. This would not happen, of course, if university professors were involved but it could be if a company identified such patterns from patient tissue samples.

Recall that the FDA does not regulate diagnostic assays like it regulates drugs, and any CLIA-certified lab can use "home brew" testing. And even if there is regulation, politics could prevent disclosure, since successful use in a jurisdiction like Europe or Japan would mobilize political pressure to have such tests in the US. Since diagnostics are unlike drugs and won't immediately kill people there will be less political will to keep them off the market.

Thanks for the comment.

The comments to this entry are closed.

October 2014

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31